Physicians' Academy for Cardiovascular Education
Member

E-counselling improves adherence in hypertensives

Mar. 21, 2017 - Dr. Rob Nolan, Toronto, ONT, Canada

PCSK9 inhibitors: From bench to bedside

Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

Troponin is an independent predictor of CV events at non-cardiac surgery

Mar. 21, 2017 - Dr. P.J. Devereaux - Hamilton, ONT, Canada

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 outcome trials: The results put into perspective of other clinical developments

Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA

LDL lowering for CVD prevention: From hypothesis to axiom

Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

Mar. 17, 2017

CV outcomes with a PCSK9 inhibitor: FOURIER study

Mar. 16, 2017
##SCROLLER_ITEMS_FULL_TITLE##

Lipid-lowering in the elderly - considering net benefit

Nov. 22, 2016 - AHA 2016 - Neil J. Stone, MD (Northwestern University Feinberg School of Medicine, Chicago, IL, USA)

E-counselling improves adherence in hypertensives

Mar. 21, 2017 - Dr. Rob Nolan, Toronto, ONT, Canada
 Dr. Rob Nolan presented the results of the double-blind randomised controlled REACH study, in which multi-medial e-counselling significantly improved antihypertensive therapy adherence, and it lowered blood pressure.

ACC 2017 Dr. Rob Nolan presented the results of the REACH study, in which multi-medial e-counselling significantly improved antihypertensive therapy adherence, and it lowered blood pressure.

PCSK9 inhibitors: From bench to bedside

Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA
Prof. Gilles Lambert describes the development since the discovery in 2002 of PCSK9 until the results of outcome trials with a PCSK9 inhibitor in 2017.

PCSK9 Expert Opinions Prof. Gilles Lambert describes the development of PCSK9 inhibitors since the discovery in 2002 of PCSK9 as a circulating protein targeting the LDL receptor for degradation. Now in 2017, results of outcome trials with a PCSK9 inhibitor are available.

Troponin is an independent predictor of CV events at non-cardiac surgery

Mar. 21, 2017 - Dr. P.J. Devereaux - Hamilton, ONT, Canada
ACC 2017 Dr. P.J. Devereaux presented the VISION study, in which hs-TNT turned out to be an independent predictor of CV events and mortality around non-cardiac surgery. A post-operative peak value was determined that indicates increased risk.

ACC 2017 Dr. P.J. Devereaux presented the VISION study, in which hs-TNT turned out to be an independent predictor of CV events and mortality around non-cardiac surgery. A post-operative peak value was determined that indicates increased risk.

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA
Prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.

PCSK9 Expert Opinions By combining all recent insights on treatment with PCSK9 inhibitors, prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.

Lowering LDL-c for a longer period of time really matters

Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA
Dr. Paul M. Ridker states that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.

PCSK9 Expert Opinions Dr. Paul M. Ridker states that from FOURIER and SPIRE it becomes clear that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.

No J-shaped curve for efficacy in PCSK9 outcome trials

Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA
Prof. Kausik Ray describes the absence of a  J-shaped curve in the PCSK9 outcome trials,  meaning there is no apparent diminution of benefit to very low LDL.

PCSK9 Expert Opinions Prof. Kausik Ray describes the practical implications of the PCSK9 outcome trials. In terms of efficacy, there is no J-shaped curve, meaning there is no apparent diminution of benefit to very low LDL

PCSK9 outcome trials: The results put into perspective of other clinical developments

Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA
Prof. Peter Sever describes the results of the FOURIER with respect to safety and efficacy and puts the data into perspective of other trials and molecules.

PCSK9 Expert Opinions Prof. Peter Sever describes the results of the FOURIER with respect to safety and efficacy. He puts the data into perspective of other trials and molecules.

LDL lowering for CVD prevention: From hypothesis to axiom

Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA
Prof. John Kastelein argues that after FOURIER and SPIRE 1&2, there can no longer be any doubt that lowering LDL is crucial for CVD prevention.

PCSK9 Expert Opinions Prof. John Kastelein explains the most important points from FOURIER and SPIRE 1&2. He argues that there can no longer be any doubt that lowering LDL is crucial for CVD prevention.

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA
Prof. John Chapman gives his personal views on the results of FOURIER and SPIRE 1&2 and the implications for LDL-c lowering in high-CV risk individuals.

PCSK9 Expert Opinions Prof. John Chapman gives his personal views on the results of FOURIER and SPIRE 1&2. Key question is whether in the light of the new data, the LDL-c goal will be maintained or lowered in high-CV risk individuals.

Initiation digoxin therapy associated with increased mortality in AF patients

Presented at ACC.17 by Renato D. Lopes

Mar. 23, 2017 - news

ACC 2017 AF patients starting digoxin treatment showed increased mortality, especially in the first 6 months, irrespective of the coexistence of HF, and digoxin concentrations >1.2 ng/ml should be avoided.

No convincing evidence of measurable verbal or nonverbal memory dysfunction due to statin

Gepresenteerd tijdens ACC.17 door Beth Taylor

Mar. 23, 2017 - news

ACC 2017 First study investigating the effects of statins on the CNS using fMRI, showed few differences between atorvastatin 80 mg and placebo in standardised neuropsychological tests.

Paroxysmal AF associated with worse clinical outcomes than persistent AF

Presented at ACC.17 by JJV McMurray

Mar. 23, 2017 - news

ACC 2017 Paroxysmal AF was associated with a higher risk of HF hospitalisation and stroke, while new-onset AF was associated with a higher risk of HF hospitalisation, death and stroke.